HK1100559A1 - N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b - Google Patents
N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein bInfo
- Publication number
- HK1100559A1 HK1100559A1 HK07105744.1A HK07105744A HK1100559A1 HK 1100559 A1 HK1100559 A1 HK 1100559A1 HK 07105744 A HK07105744 A HK 07105744A HK 1100559 A1 HK1100559 A1 HK 1100559A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- apolipoprotein
- inhibitors
- piperidine substituted
- aryl piperidine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03104601 | 2003-12-09 | ||
| PCT/EP2004/053280 WO2005058824A2 (en) | 2003-12-09 | 2004-12-06 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprote in b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1100559A1 true HK1100559A1 (en) | 2007-09-21 |
Family
ID=34684566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK07105744.1A HK1100559A1 (en) | 2003-12-09 | 2007-05-30 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8772494B2 (xx) |
| EP (1) | EP1694644B1 (xx) |
| JP (1) | JP4790626B2 (xx) |
| KR (1) | KR101125120B1 (xx) |
| CN (1) | CN100548985C (xx) |
| AT (1) | ATE548350T1 (xx) |
| AU (1) | AU2004299295B2 (xx) |
| BR (1) | BRPI0417469B8 (xx) |
| CA (1) | CA2547243C (xx) |
| EA (1) | EA009081B1 (xx) |
| ES (1) | ES2383179T3 (xx) |
| HK (1) | HK1100559A1 (xx) |
| IL (1) | IL176171A (xx) |
| NO (1) | NO337251B1 (xx) |
| NZ (1) | NZ546964A (xx) |
| SG (1) | SG149001A1 (xx) |
| UA (1) | UA83510C2 (xx) |
| WO (1) | WO2005058824A2 (xx) |
| ZA (1) | ZA200604718B (xx) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1948629A1 (en) * | 2005-10-31 | 2008-07-30 | Janssen Pharmaceutica N.V. | Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
| US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
| JP5198430B2 (ja) | 2006-04-03 | 2013-05-15 | サンタリス ファーマ アー／エス | ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物 |
| MY162210A (en) | 2006-04-03 | 2017-05-31 | Roche Innovation Ct Copenhagen As | Pharmaceutical composition |
| US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
| JP2010521193A (ja) | 2007-03-22 | 2010-06-24 | サンタリス ファーマ アー／エス | Ａｐｏ−ｂ１００発現の阻害のためのｒｎａアンタゴニスト化合物 |
| WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
| ES2463665T3 (es) | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
| AU2009221064B2 (en) | 2008-03-07 | 2014-12-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
| EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
| ES2599979T3 (es) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
| WO2011009697A1 (en) | 2009-07-21 | 2011-01-27 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
| RS59986B1 (sr) | 2013-06-27 | 2020-03-31 | Roche Innovation Ct Copenhagen As | Antisens oligomeri i konjugati koji ciljno deluju na pcsk9 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826412D0 (en) * | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0013378D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| JO2390B1 (en) | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Diphenylcarboxamides act as lipid-lowering agents |
| GB0109287D0 (en) * | 2001-04-12 | 2001-05-30 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0129015D0 (en) * | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
| UA79300C2 (en) * | 2002-08-12 | 2007-06-11 | Janssen Pharmaceutica Nv | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
-
2004
- 2004-06-12 UA UAA200605783A patent/UA83510C2/uk unknown
- 2004-12-06 WO PCT/EP2004/053280 patent/WO2005058824A2/en active Application Filing
- 2004-12-06 NZ NZ546964A patent/NZ546964A/en not_active IP Right Cessation
- 2004-12-06 ES ES04804685T patent/ES2383179T3/es active Active
- 2004-12-06 BR BRPI0417469A patent/BRPI0417469B8/pt not_active IP Right Cessation
- 2004-12-06 CA CA2547243A patent/CA2547243C/en not_active Expired - Fee Related
- 2004-12-06 AT AT04804685T patent/ATE548350T1/de active
- 2004-12-06 EP EP04804685A patent/EP1694644B1/en active Active
- 2004-12-06 JP JP2006543538A patent/JP4790626B2/ja not_active Expired - Fee Related
- 2004-12-06 SG SG200809026-8A patent/SG149001A1/en unknown
- 2004-12-06 CN CNB2004800362613A patent/CN100548985C/zh not_active Expired - Fee Related
- 2004-12-06 AU AU2004299295A patent/AU2004299295B2/en not_active Ceased
- 2004-12-06 KR KR1020067013049A patent/KR101125120B1/ko active IP Right Grant
- 2004-12-06 US US10/580,530 patent/US8772494B2/en not_active Expired - Fee Related
- 2004-12-06 EA EA200601120A patent/EA009081B1/ru not_active IP Right Cessation
-
2006
- 2006-06-07 IL IL176171A patent/IL176171A/en active IP Right Grant
- 2006-06-08 ZA ZA200604718A patent/ZA200604718B/en unknown
- 2006-07-04 NO NO20063103A patent/NO337251B1/no not_active IP Right Cessation
-
2007
- 2007-05-30 HK HK07105744.1A patent/HK1100559A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| UA83510C2 (xx) | 2008-07-25 |
| WO2005058824A2 (en) | 2005-06-30 |
| JP2007513921A (ja) | 2007-05-31 |
| AU2004299295B2 (en) | 2010-07-15 |
| ZA200604718B (en) | 2007-10-31 |
| JP4790626B2 (ja) | 2011-10-12 |
| EP1694644B1 (en) | 2012-03-07 |
| ATE548350T1 (de) | 2012-03-15 |
| IL176171A (en) | 2013-08-29 |
| CN100548985C (zh) | 2009-10-14 |
| BRPI0417469B8 (pt) | 2021-05-25 |
| NO337251B1 (no) | 2016-02-22 |
| NO20063103L (no) | 2006-09-05 |
| KR20060111628A (ko) | 2006-10-27 |
| WO2005058824A3 (en) | 2005-10-27 |
| US20070099934A1 (en) | 2007-05-03 |
| CN1890217A (zh) | 2007-01-03 |
| US8772494B2 (en) | 2014-07-08 |
| CA2547243A1 (en) | 2005-06-30 |
| EP1694644A2 (en) | 2006-08-30 |
| AU2004299295A1 (en) | 2005-06-30 |
| KR101125120B1 (ko) | 2012-03-21 |
| BRPI0417469A (pt) | 2007-04-10 |
| SG149001A1 (en) | 2009-01-29 |
| CA2547243C (en) | 2012-10-23 |
| EA009081B1 (ru) | 2007-10-26 |
| ES2383179T3 (es) | 2012-06-18 |
| EA200601120A1 (ru) | 2006-10-27 |
| NZ546964A (en) | 2009-03-31 |
| IL176171A0 (en) | 2006-10-05 |
| BRPI0417469B1 (pt) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1100559A1 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | |
| HRP20050103B1 (hr) | N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b | |
| SE0200920D0 (sv) | Novel compounds | |
| HUP0303876A3 (en) | Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv | |
| TW200613243A (en) | Novel compounds | |
| DE60315336D1 (de) | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) | |
| GEP20074197B (en) | 5ht2c receptor modulators | |
| IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
| EA200601660A1 (ru) | Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами | |
| MY143599A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
| SE0300480D0 (sv) | Novel compounds | |
| TW200626553A (en) | Novel compounds | |
| TW200639156A (en) | New compounds | |
| JO2409B1 (en) | Second-phenyl carboxy amides are useful as lipid-lowering agents | |
| JO2390B1 (en) | Diphenylcarboxamides act as lipid-lowering agents | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| MX2009006010A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2. | |
| SE0401763D0 (sv) | Compounds | |
| EA200870223A1 (ru) | Производные бензоизоиндола для лечения боли | |
| NO20063790L (no) | Substituerte azetidin sammensetninger som cyclooxygenase-1-cyclooxygenase-2-inhibitorer, og deres fremstilling og anvendelse som medikamenter | |
| SE0202693D0 (sv) | Compounds | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
| AU2001244999A1 (en) | Naphthamide neurokinin antagonists for use as medicaments | |
| JO2529B1 (en) | Ariel pybradine is a substitute for phenyl carboxymides | |
| SE0202287D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20211208 |